Press Releases AnaptysBio, Inc.

Equities

ANAB

US0327241065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
23.43 ^USD	-2.01%		-2.13%	+9.38%

May. 09	AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update	May. 09	GL
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)	May. 09	GL
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties	May. 09	GL
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 11	GL
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	Feb. 29	GL
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting	Feb. 29	AQ
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	Jan. 31	GL
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference	Jan. 31	AQ
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals	Nov. 27	GL
Anaptys Named a BioSpace 2024 Best Places to Work Winner	Nov. 07	GL
Anaptys Named a BioSpace 2024 Best Places to Work Winner	Nov. 07	AQ
Acne Vulgaris Pipeline\| Clinical Trials, Key Companies - Novan, Bausch Health AOBiome, Ascletis Pharmaceuticals, AnaptysBio, Botanix Pharmaceuticals	Nov. 07	AQ
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update	Nov. 02	GL
Anaptys Announces Participation in November Investor Conferences	Nov. 01	GL
Anaptys Announces Participation in November Investor Conferences	Nov. 01	AQ
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress	23-10-11	GL
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress	23-10-11	AQ
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25	23-10-09	GL
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25	23-10-09	AQ
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)	23-10-09	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AnaptysBio, Inc.

Equities

ANAB

US0327241065

Press Releases

Filters